The increasing adoption of strategies such as acquisitions & agreement by key players is expected to drive the market growth over the forecast period. For instance, in September 2020, Hester Biosciences Limited signed an agreement with IVRI (Indian Veterinary Research Institute), an institute under the Indian Council of Agricultural Research (ICAR), to acquire Brucella vaccine technology for developing the Brucella Abortus S19 Delta Pevaccine from IVRI Hester, which manufactures the conventional Brucella Abortus S19 vaccine and supplies it to all the states in India. The S19 Delta Per new generation vaccine technology developed by IVRI will be a step forward towards developing a Brucella vaccine with enhanced immunogenicity and safety, assuring lifelong immunity with a single shot in calf-hood.
The global Brucellosis Vaccines Market is estimated to be valued at US$ 224.64 million in 2022 and expected to exhibit a CAGR of 4.7% over the forecast period (2022-2030)
Figure 1. Global Brucellosis Vaccines Market Share (%) in Terms of Value, By Region, 2022
Increasing investments by key players in market for expansion of brucellosis manufacturing facilities is expected to drive market growth over the forecast period.
For instance, in August 2019, Biovet Private Ltd, an animal health vaccine producing company located in Karnataka, India, announced that it will invest US$ 26,212,600 (Rs 200 crore) for expanding its foot & mouth and brucellosis vaccine manufacturing facilities in Malur, Karnataka, India. This is expected to drive market growth over the forecast period.
|Base Year:||2021||Market Size in 2022:||US$ 224.64 Mn|
|Historical Data for:||2017 to 2021||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||4.7%||2030 Value Projection:||US$ 324.83 Mn|
Merck & Co., Inc., CZ Vaccines, Colorado Serum Company, Indian Immunologicals Ltd., Hester Biosciences Limited, Veterinary Technologies Corporation, Jordan Bio-industries Center, Laboratorios Tornel, Fivet Animal Health, and VETAL Animal Health Products Inc.
|Restraints & Challenges:||
Figure 2. Global Brucellosis Vaccines Market Share (%), by Type, 2022
Global Brucellosis Vaccines Market: Restraint
Drawbacks associated with use of brucellosis vaccines is expected to act as a restraint for the global brucellosis vaccines market growth over the forecast period. For instance, according to an article published by the Journal of Veterinary Science, an international, peer-reviewed, open-access journal of veterinary medicine, in August 2017, currently available brucellosis vaccines exhibit one or more major drawbacks such as residual virulence and serodiagnostic interference. Moreover, according to an article published by the journal Veterinary Research, an open access journal that publishes high quality novel research and review articles, in July 2015, although the available vaccines are effective in controlling brucellosis, they have numerous drawbacks such as interference with diagnostic tests, pathogenicity for humans, and potential to cause abortion in pregnant animals, among others.
Major players operating in the global brucellosis vaccines market include Merck & Co., Inc., CZ Vaccines, Colorado Serum Company, Indian Immunologicals Ltd., Hester Biosciences Limited, Veterinary Technologies Corporation, Jordan Bio-industries Center, Laboratorios Tornel, Fivet Animal Health, and VETAL Animal Health Products Inc.
Brucellosis is an infectious disease caused by bacteria. Animals that are most commonly infected include sheep, cattle, goats, pigs, and dogs, among others. These disease can also occur in humans when they are in contact with infected animals or animal products contaminated with bacteria.
Moreover, RB51 Vaccine, S19 Vaccine, B19 Vaccine and Others (45/20 vaccine, SR82 vaccine, etc.) are the type of vaccine used for the brucellosis in animals.
Furthermore, increasing launches of brucellosis vaccination programmes is expected to drive the market growth over the forecast period.
In August 2021, brucella vaccination program was launched at Thoubal, Manipur, India for the control and eradication of brucellosis in female calves of 4-8 months age group.
Increasing prevalence of brucellosis is expected to drive the global brucellosis vaccines market growth over the forecast period. For instance, according to an article published by the National Center for Biotechnology Information, a series of databases relevant to biotechnology and biomedicine, brucellosis is the world’s most widespread zoonotic disease, a type of disease that passes from an animal to a human. The source stated that there are a reported 500,000 cases of human brucellosis each year, globally. However, true incidence is estimated to be 5,000,000 to 12,500,000 cases each year, globally.
According to the same source, brucellosis is recognized as the world’s most common laboratory-acquired infection.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.